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human GN. Based on these findings, together with the knownExpression of macrophage migration inhibitory factor in hu-
pathogenic role of MIF in experimental GN, we propose thatman glomerulonephritis.
MIF is an attractive therapeutic target in the treatment ofBackground. We have recently demonstrated that macro-
progressive forms of GN.phage migration inhibitory factor (MIF) plays a pathogenic
role in experimental glomerulonephritis (GN). The aim of the
current study was to investigate MIF expression in human GN.
Methods. MIF expression was examined by in situ hybridiza-
Macrophage migration inhibitory factor (MIF) wastion and immunohistochemistry staining in 65 biopsies from a
originally described as a product of activated T cells thatvariety of glomerulonephridities.
Results. There is constitutive expression of MIF mRNA and inhibits macrophage migration in vitro and promotes
protein in normal human kidney that is largely restricted to macrophage accumulation in the delayed-type hypersen-
tubular epithelial cells and to some glomerular epithelial cells. sitivity (DTH) reaction [1, 2]. Recent studies have shownThere was little change in the pattern of MIF expression in
that MIF plays a pivotal role in regulating the immunenonproliferative forms of GN such as minimal change disease
response [3]. Macrophage accumulation and skin swell-and membranous GN. However, there was a marked increase
in both glomerular and tubular MIF expression in proliferative ing in mouse skin DTH response can be blocked by the
forms of GN, including focal segmental glomerulosclerosis administration of a neutralizing anti-MIF antibody [4].
(FGS), lupus nephritis, crescentic GN, and mesangiocapillary In addition, MIF has been shown to play a central roleproliferative GN. The prominent macrophage and T-cell infil-
in endotoxemia [5–8] and in primary T-cell activationtrate in these diseases were largely restricted to areas with
and proliferation [9]. Furthermore, MIF is the only mole-marked up-regulation of MIF expression, contributing to glo-
merular hypercellularity, glomerular focal segmental lesions, cule described thus far that can override the antiinflam-
crescent formation, tubulitis, and granulomatous lesions. De matory action of glucocorticoids [10].
novo MIF expression was evident in glomerular endothelial The view that MIF is solely a T-cell product has beencells and mesangial cells in proliferative forms of GN. In addi-
changed with the demonstration that MIF is constitu-tion, many infiltrating macrophages and T cells showed MIF
tively expressed in many tissues [6, 11–18]. The 12 kdmRNA and protein expression. Quantitative analysis found
that increased glomerular and tubular MIF expression gave MIF protein is stored within the cytoplasm and then
a highly significant correlation with macrophage and T-cell released when cells are stimulated by factors such as
accumulation, the severity of histologic lesions, and the loss of endotoxin [7, 11]. In the rat kidney, MIF is constitutivelycreatinine clearance.
expressed by glomerular and tubular epithelial cells [19].Conclusions. Renal MIF expression is markedly up-regu-
Renal MIF expression is up-regulated in experimentallated in proliferative forms of human GN, and this correlates
with leukocyte infiltration, histologic damage, and renal func- kidney disease, including rat models of anti-glomerular
tion impairment. These results suggest that MIF may be an basement membrane (anti-GBM) crescentic glomerulo-
important mediator of renal injury in progressive forms of nephritis (GN), Tamm-Horsfall protein-induced tubulo-
interstitial nephritis, and anti–Thy-1 mesangioprolifera-
tive nephritis [19–22]. In each of these disease models,Key words: MIF, glomerulonephritis, epithelial cells, T cells, progres-
sive renal disease. up-regulation of MIF expression is closely associated
with macrophage accumulation and tissue damage.Received for publication May 24, 1999
Antibody-based blocking studies have provided strongand in revised form September 1, 1999
Accepted for publication September 9, 1999 evidence that MIF plays a pathologic role in kidney
disease. The administration of a neutralizing anti-MIFÓ 2000 by the International Society of Nephrology
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Table 1. Classification, renal function and histologic changes in patients wih glomerulonephritis
Glomerular
Glomerular segmental Glomerular TubulointerstitialSerum Creatinine
hypercellularity lesions crescents lesionsNo. of Proteinuria creatinine clearance
Disease patients g/24 h lmol /L mL/min %
Normal 5 0.00460.002 5264.4 11366.8 0060.0 0060.0 0060.0 0060.0
MCD 8 3.9 62.6 8266.5 10464.7 30.464.7 1163.4 0060.0 663.6
Non-IgA MPGN 7 1.460.8 6865.6 108614.5 45613.4 0060.0 0060.0 861.7
IgAN 11 4.261.9 106616.5 9967.1 4868.7 1867.4 0060.0 961.7
MGN 6 8.4 61.9b 10569.2 92618.8 54.568.0 4267.5d 661.7 3965.6
MCPGN 5 3.7 61.9 437670.0b 2266.2c 69613.2d 55617.8e 1163.1 7063.5f
Crescent GN 10 1.361.9 489690.0c 18.867.0c 6566.4d 8164.8f 4667.5f 7463.5f
FGS 11 5.161.6a 155627.9 69612.3a 5467.0 58613.2e 1067.8 44612.2e
SLE 7 6.361.2a 200675.3 55613.1b 7964.1e 8764.8f 2967.8 64610.8f
Abbreviations are: MCD, minimal change disease; Non-IgA MPGN, non-IgA mesangial proliferative GN; IgAN, IgA nephropathy; MGN, membranous GN;
MCPGN, mesangiocapillary proliferative GN; Crescentic GN; FGS, focal glomerular sclerosis; SLE, systemic lupus WHO class IV.
a P , 0.05, bP , 0.01, cP , 0.001 compared to normal
d P , 0.05, eP , 0.001, fP , 0.001 compared to MCD
antibody significantly inhibits macrophage and T-cell ac- 30 glomerular cross-sections (gcs) per biopsy. Similarly,
the percentage of glomeruli exhibiting hypercellularitycumulation and histologic damage, reduces proteinuria,
and prevents a loss of renal function during the induction was scored. Hypercellularity was assessed as more than
80 cells/gcs, with normal being less than 60 cells/gcs.phase of rat crescentic anti-GBM GN [23]. In a further
study, the administration of this anti-MIF antibody was The percentage of the tubulointerstitial area exhibiting
tubulitis, tubular dilation, atrophy, or fibrosis was as-shown to reverse partially the progressive phase of estab-
lished crescentic GN in the rat [24]. sessed on H&E stained sections. All scoring was per-
formed on blinded sections.The aim of this study was to investigate the importance
of renal MIF expression in human GN. In situ hybridiza-
Antibodies and probestion and immunohistochemistry staining were used to
demonstrate MIF gene and protein expression in biopsy The mouse anti-MIF monoclonal antibody (mAb)
specimens from a cohort of 65 patients with different III.D.9 was raised against purified recombinant mouse
forms of GN. MIF protein (which has a 90% homology with human
MIF protein). The III.D.9 antibody recognizes recombi-
nant mouse and human MIF by Western blotting (un-
METHODS published observations). Furthermore, the specificity of
Patients anti-MIF antibody has been determined by the coexpres-
sion of MIF mRNA and protein within normal and dis-A total of 65 renal biopsies from the Department of
ease kidney tissue sections using double in situ hybridiza-Nephrology, Monash Medical Center and the Depart-
tion and immunohistochemistry staining [19, 25]. Otherment of Nephrology, First Affiliated Hospital of Sun
mAb used in this study include KP1 (mouse anti-CD68Yat-Sen University of Medical Sciences, was examined
mAb labels most monocytes and macrophages) [26] and(37 males and 28 females; average age 43 years, range
UCHL1 (mouse anti-CD45RO mAb recognizes mature,13 to 82). All patients were diagnosed on the basis of
activated T-cells and a subset of resting T cells) [27].biopsy examination. Measurements of 24-hour protein
The KP1 mAb, UCHL1 mAb, peroxidase and alkalineexcretion, serum creatinine, and creatinine clearance
phosphatase-conjugated goat antimouse IgG, mouse per-were taken at the time of biopsy for each patient. Mor-
oxidase antiperoxidase complexes (PAP), and mouse al-phologically normal human kidney was obtained from
kaline phosphatase anti-alkaline phosphatase complexesthe unaffected areas of five renal tumor nephrectomy
specimens and used as control tissue in this study. The (APAAP) were all purchased from Dakopatts (Glost-
disease classifications, numbers of patients, clinical and rup, Denmark). A mouse anti-rat CD45 mAb (OX-1),
histologic data are shown in Table 1. which does not react with human tissues, was used as a
negative control.
Histopathology A 369 bp fragment of human MIF cDNA was ampli-
fied by reverse transcription-polymerase chain reactionSections (4 mm) of formalin-fixed, paraffin-embedded
biopsy tissue were stained with hematoxylin and eosin (RT-PCR) using the primers 59 TCCTTCTGCCAT
CATGCCGA 39 and 59 TGCGGCTCTTAGGCGAA(H&E). The percentage of glomeruli exhibiting segmen-
tal proliferative lesions or crescents was scored in 10 to GGTG 39. The PCR product was cloned using a TA
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cloning kit (Invitrogen, Carlsbad, CA, USA). The PCR Melbourne, Australia). Sections were counterstained with
product was verified by DNA sequencing in both direc- periodic acid-Schiff minus hematoxylin and mounted in
tions. A 520 bp fragment containing the MIF cDNA was an aqueous medium.
subcloned into the pCR II plasmid (Stratagene, La Jolla, Controls for the two color immunostaining procedure
CA, USA). The linearized plasmid was used to prepare included performing single color staining for each anti-
digoxigenin (DIG)-labeled antisense and sense cRNA body on separate sections in a limited number of cases.
probes for in situ hybridization according to the manufac- The mAb staining patterns were very similar in both
turer’s protocol (Roche Diagnostics GmbH, Mannheim, one- and two-color immunostaining techniques, demon-
Germany). The efficiency of probe labeling was deter- strating that the microwave procedure was efficient in
mined by dot blotting according to the manufacturer’s blocking antibody cross-reactivity.
protocol (Roche Diagnostics GmbH). Briefly, serial two-
In situ hybridizationfold dilutions of the probe were dotted onto a Nylon
membrane, dried, cross-linked by ultraviolet irradiation, In situ hybridization was performed on 4 mm paraffin
and then detected using alkaline phosphatase-conju- sections of formalin-fixed tissue using a microwave-based
gated F(ab) fragments of sheep anti-DIG antibody fol- protocol [19, 20, 29]. After dewaxing, sections were
lowed by color development with X-phosphate/NBT. treated with a microwave oven for 10 minutes, as out-
The titration pattern of the probe was compared with a lined previously in this article, incubated with 0.2
standard of known specific activity. Sense and antisense mol/L HCl for 15 minutes, followed by 1% Triton
probes of equivalent specific activity were used. The X-100 for 15 minutes, and then digested for 20 minutes
specificity of the antisense probe was confirmed by with 10 mg/mL proteinase-K at 378C (Roche Diagnos-
Northern blotting in which a 0.6 kb mRNA species was tics). Sections then were washed in 2 3 standard saline
detected in RNA isolated from a green monkey tubular citrate (SSC), prehybridized, and then hybridized with
epithelial cell line (BSC-1). The sense probe failed to 0.5 ng/mL DIG-labeled sense or antisense cRNA probe
detect MIF mRNA. The specificity of human MIF probe overnight at 428C in a hybridization buffer containing
was verified by a similar expression pattern identified by 50% deionized formamide, 4 3 SSC, 1 mg/mL salmon
in situ hybridization and the anti-MIF mAb staining in sperm DNA, and 1 mg/mL yeast tRNA. Sections were
normal and disease human kidney [25]. washed finally in 0.1 3 SSC at 428C, and the hybridized
probe was detected using alkaline phosphatase-conju-Immunohistochemistry
gated sheep anti-DIG F(ab) fragments and color devel-
One and two color immunohistochemical staining was
opment with NBT/X-phosphate.
performed on 4 mm paraffin sections of formalin-fixed
Controls employed a sense MIF cRNA probe labeledtissue using a previously described microwave-based
to the same specific activity as the antisense probe, ormethod [19, 25, 28]. Briefly, sections were treated by 10
the probe was omitted completely. No staining was seenminutes of microwave oven heating in 0.01 mol/L sodium
in either normal or diseased kidney using the sense probecitrate, pH 6.0, at 2450 MHz and 800 W. This treatment
or with no probe at all.markedly enhanced antibody access to the MIF, KP1,
and UCHL1 antigens. Sections were then preincubated Quantitation of tissue staining
with 10% fetal calf serum (FCS) and 10% normal goat
The number of cells labeled by immunostaining or inserum in phosphate-buffered saline (PBS) for 20 min-
situ hybridization was counted under high power (3400)utes, drained and labeled with KP1 or UCHL1 mAb for
in all glomeruli in each biopsy (range; 4 to 15 gcs per60 minutes, and washed (33) in PBS and endogenous
case) and was expressed as the number of labeled cellsperoxidase inactivated by incubation in 0.3% H2O2 in
per gcs. To assess tubulointerstitial staining, the numbermethanol. Sections then were washed in PBS, incubated
of labeled interstitial cells was counted in the entire corewith peroxidase-conjugated goat anti-mouse IgG, washed
of the biopsy in high-power fields by means of a 0.02in PBS, and incubated with mouse PAP complexes and
mm2 graticule fitted in the eyepiece of the microscopedeveloped with 3,3-diaminobenzidine to produce a brown
and expressed as cells per mm2. MIF expression by mac-color. For double immunostaining, a second round of
rophages (KP11MIF1 cells) and T cells (UCHL11MIF1microwave oven heating was used to denature bound im-
cells) was quantitated under high power in double-munoglobulin, thereby preventing antibody cross-reac-
stained sections. Tubular MIF staining was scored fromtivity [28]. Sections then were preincubated as described
the entire biopsy (range, 500 to 1000 tubules) and ex-previously in this article and labeled with the anti-MIF
pressed as percentage positive tubules. Because most (60mAb overnight at 48C. After washing in PBS, sections
to 80%) tubules show variable weak immunostainingwere incubated sequentially with alkaline phosphatase-
for MIF protein in normal human kidney, only tubulesconjugated goat anti-mouse IgG and mouse APAAP and
then developed with Fast Blue BB Salt (Ajax Chemicals, exhibiting moderate to strong MIF staining were scored.
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Data are expressed as the mean 6 sem. All counting was renal function, mild histologic lesions, and little macro-
phage and T-cell infiltration (Table 1 and Fig. 4).performed on blinded slides.
In contrast, there was a marked up-regulation of
Statistical analysis MIF mRNA and protein expression in severe prolifer-
ative GN, including mesangiocapillary proliferative GNStatistical analysis was performed using GraphPad
Prism 2.00 (GraphPad Software, Inc., San Diego, CA, (MCPGN), focal segmental glomerular sclerosis (FGS),
lupus nephritis, and crescentic GN. A prominent featureUSA). Differences in MIF expression, macrophage and
T-cell accumulation, renal function, and histologic dam- in these diseases was the increase in the number and
the intensity of MIF mRNA and protein staining withinage were assessed by one-way analysis of variance. The
Pearson single correlation coefficient analysis was used areas of moderate to severe glomerular and tubulointer-
stitial damage (Figs. 1 C–F and 2 B–F). In contrast, areasto compare glomerular and tubular MIF expression with
macrophage and T-cell accumulation, renal function, and with mild or no evidence of damage showed no obvious
change in MIF staining. Indeed, up-regulation of MIFhistologic damage.
expression by glomerular endothelial and epithelial cells
in MCPGN (Figs. 1C and 2B), FGS (Figs. 1D and 2C),
RESULTS
and crescentic GN (Figs. 1F and 2D) was associated with
Normal human kidney prominent KP11 macrophage accumulation, contribut-
ing to the development of glomerular hypercellularity,In situ hybridization and immunohistochemistry showed
that MIF is constitutively expressed in normal human focal segmental lesions, and crescent formation. Up-reg-
ulation of MIF mRNA and protein by tubular epithelialkidney. MIF mRNA and protein are expressed by some
glomerular visceral and parietal epithelial cells (Figs. cells was restricted to areas of severe tubulointerstitial
damage in MCPGN (Fig. 1C), lupus nephritis (Fig. 1D),1A, 2A, and 3). Most tubular epithelial cells show weak
immunostaining for MIF protein, whereas in situ hybrid- and crescentic GN (Figs. 1F and 2 E, F). Double immuno-
staining showed that focal interstitial macrophage andization detects a weak signal for MIF mRNA in less than
half of the tubules (Fig. 1A, 2A, and 3). T-cell accumulation occurs in areas with up-regulation
of tubular MIF expression, resulting in severe tubulitis
MIF expression in nonproliferative glomerulonephritis and granulomatous lesion formation (Fig. 2 E, F). In
addition, double immunostaining demonstrated that aThere was no change in both the percentage of inten-
sity of renal MIF expression in minimal change disease high proportion of infiltrating macrophages (85.5 6
17%) and T cells (63.1 6 11.7%) within the kidney was(MCD) compared with that constitutively expressed in
normal human kidney. There was an increase in glomeru- shown to express MIF in proliferative forms of GN (Fig.
4), and these infiltrating cells were localized to areas oflar MIF immunostaining in membranous GN (MGN),
which was largely caused by MIF expression by podo- severe tissue damage (Fig. 2B–F). The percentage of
macrophages and T cells expressing MIF was muchcytes, but this was not accompanied by an increase in
tubular MIF expression (Figs. 1B and 3). Little macro- greater in severe proliferative compared with nonprolif-
erative forms of GN (Fig. 4). An interesting observationphage or T-cell infiltration was evident in these diseases
(Fig. 4). was the mesangial pattern of MIF expression evident in
IgAN and non-IgA mesangial proliferative GN (Fig. 1E).
MIF expression in proliferative glomerulonephritis
Correlation of MIF expression with leukocyteThere was a modest up-regulation in renal MIF ex-
accumulation, histologic damage, and renal functionpression in non-IgA mesangial proliferative GN (non-
IgA MPGN) and IgA nephropathy (IgAN; Fig. 3). These The relationship between renal MIF expression and
clinical and histologic parameters was examined usingpatient groups had mild disease, as reflected by normal
c
Fig. 1. In situ hybridization detecting macrophage migration inhibitory factor (MIF) mRNA expression in sections of normal and diseased human
kidney. (A) Constitutive MIF mRNA expression by some glomerular and parietal epithelial cells and by tubular epithelial cells in a normal human
kidney. (B) Membranous glomerulonephritis (GN) showing a mild to moderate up-regulation of glomerular MIF mRNA expression, largely by
podocytes, but tubular MIF mRNA is unchanged compared to that seen in normal human kidney. (C ) Mesangiocapillary proliferative GN
(MCPGN), showing marked up-regulation of MIF mRNA by both glomerular and tubular epithelial cells. The increased MIF mRNA expression
is most prominent within severe glomerular and tubulointerstitial lesions. (D) Lupus nephritis showing strong MIF mRNA expression in focal
glomerular and tubulointerstitial lesions. Note that many of the infiltrating mononuclear cells within interstitial lesions express MIF mRNA. (E)
IgAN showing distinct MIF mRNA expression by glomerular mesangial cells in addition to expression by glomerular epithelial cells. (F ) Crescentic
GN showing strong MIF mRNA expression within both the glomerulus and tubulointerstitium, contributing to crescent formation (*) and severe
tubulointerstitial lesions. In addition, expression of MIF mRNA by vascular endothelial cells (arrowheads) was clearly identified in severe forms
of GN (C, D, and F). Original magnification: 3100 (C), 3250 (A, B, D, and F), 3400 (E).
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Fig. 3. Quantitation of renal MIF mRNA and protein expression in normal and diseased human kidney. Staining of tissue sections for MIF mRNA
and MIF protein was quantitated in the glomerulus (A and B) and in tubules (C and D) as described in the Methods section. Data are expressed
as the mean 6 sem. *P , 0.05; **P , 0.01; ***P , 0.001 compared with normal kidney.
data from all patients in the study (Table 2). The number MIF gave a highly significant correlation with interstitial
macrophage and T-cell infiltration, tubulointerstitial dam-of glomerular cells expressing MIF gave a highly signifi-
cant correlation with glomerular macrophage and T cell age, and renal function impairment. However, neither
glomerular nor tubular MIF expression correlated withinfiltration, glomerular lesions, and renal function deteri-
oration. Similarly, the percentage of tubules expressing proteinuria (Table 2).
b
Fig. 2. Double immunohistochemistry staining of MIF protein (blue) and infiltrating macrophages and T cells (brown) in normal and diseased
human kidney. (A) Constitutive expression of MIF protein by some glomerular and parietal epithelial cells and by most tubular epithelial cells in
normal human kidney. (B) MCPGN showing a marked increase in MIF protein staining by glomerular endothelial cells (arrowheads) in association
with a prominent infiltrate of KP11 macrophages (brown). (C ) Focal glomerulosclerosis (FGS) showing up-regulation of glomerular MIF expression
with focal accumulation of KP11 macrophages (brown). (D) Crescentic GN showing a dramatic increase in glomerular MIF immunostaining
together with prominent infiltration of KP11 macrophages (brown), resulting in severe glomerular damage and crescent formation (*). (E )
Crescentic GN showing marked up-regulation of MIF expression by tubular epithelial cells in association with prominent accumulation of KP11
macrophages (brown), leading to multinucleated giant cells (arrows) and granulomatous lesion formation. (F ) Crescentic GN showing marked
up-regulation of glomerular and tubular MIF expression in association with prominent infiltration of UCHL11 T cells (brown) and the development
of severe tubulitis (*). Note that many of the macrophages (B–E) and T cells (F) labeled in brown were double stained for MIF (blue). Sections
were counterstained with periodic acid-Schiff minus hematoxylin. (Original magnification: 3100 A, F, and 3250 B–E).
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Fig. 4. Quantitation of MIF expression by infiltrating mononuclear cells in normal and diseased human kidney. Staining of tissue sections for
KP11 macrophages (h), UCHL11 T cells (h), and cells double stained for MIF (KP11MIF1 and UCHL11MIF1, j) were quantitated in the
glomerulus (A and C) and tubulointerstitium (B and D). Data are expressed as the mean 6 sem. The parentheses are the average percentage of
glomerular and interstitial macrophages or T cells expressing MIF. *P , 0.05; **P , 0.01; ***P , 0.001 compared with normal kidney.
DISCUSSION MIF expression, leading to the development of severe
tissue damage such as glomerular focal segmental lesionThis study has shown that glomerular and tubulointer-
and crescent formation, tubulitis, and granulomatous le-stitial MIF expression is up-regulated in proliferative
sions. These results, together with the known functionsforms of GN, suggesting that local production of this
of this molecule, suggest that MIF causes renal injury inkey inflammatory molecule plays an important role in
human GN by inducing macrophage and T-cell accumu-mediating progressive renal injury in human GN.
lation and the subsequent activation of these cells, lead-Renal MIF expression was largely unchanged in mild
ing to immune-cell–mediated tissue damage.forms of GN, but was markedly up-regulated in the more
The current findings support the results of a previoussevere forms of disease. When analyzing the patient pop-
study in which blood lymphocytes cultured from patientsulation as a whole, glomerular and tubular MIF expres-
with anti-GBM GN were shown to produce MIF bioac-sion gave a highly significant correlation with macro-
tivity [30]. In addition, a recent study of human renalphage and T-cell accumulation, histologic damage, and
allograft rejection found that renal MIF expression isthe loss of renal function. Indeed, macrophage and
T-cell infiltration was largely restricted to areas of strong increased in rejecting allografts, but not in nonrejecting
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Table 2. Correlation of glomerular and tubular macrophage migration inhibitory factor (MIF) immunostaining with histologic damage and
renal function in human glomerulonephritis (GN)
Macrophage T-cell Glomerular Glomerular Tubulointerstitial Serum Creatinine
infiltration infiltration hypercell seg. lesions Crescent lesions Proteinuria creatinine clearance
Glomerular 0.70 0.24 0.48 0.77 0.53 — 0.02 0.54 20.66
MIF1ve cells P,0.0001 P,0.05 P,0.001 P,0.0001 P50.0002 NS P,0.0001 P,0.0001
MIF1ve 0.76 0.66 — — — 0.67 20.02 0.55 20.62
Tubules % P,0.0001 P,0.0001 P,0.0001 NS P,0.0001 P,0.0001
Data from all patients were combined for this analysis using the Pearson single correlation coefficient.
allografts [25]. Renal MIF expression was found to corre- The use of two-color immunostaining showed that
many infiltrating macrophages and T cells express MIFlate with macrophage and T-cell infiltration, the severity
of graft rejection, and the loss of renal function [25]. All in human GN. Compared with mild forms of disease,
proliferative forms of GN not only had a greater absoluteof these findings indicate that MIF is a key mediator in
human immunologic renal injury. number of MIF-positive macrophages and T cells, but
there was also a higher proportion of MIF expression.The pathological significance of MIF production has
been tested in a rat model of crescentic anti-GBM GN. Currently we do know the relative importance of MIF
production by intrinsic renal cells versus that of infiltrat-The pattern of increased renal MIF expression in this
disease model is similar to that seen in human crescentic ing macrophages and T-cells, but it is likely that MIF pro-
duction by both cell types contributes to renal damage.GN in this study [19, 20]. Treatment of rat anti-GBM
GN with a neutralizing anti-MIF antibody substantially An interesting observation in normal human kidney
and nonproliferative forms of GN was that more tubulesreduced glomerular and interstitial macrophage and
T-cell infiltration, inhibited T-cell activation, suppressed were positive for MIF protein than were positive for
MIF mRNA. Although this could be due to a differenceproteinuria, and prevented a loss of creatinine clearance
[23]. These effects were attributed to the ability of MIF in the sensitivity in the two detection methods, this does
not appear to be the case because equal numbers ofblockade to prevent up-regulation of renal interleukin-1
(IL-1) production and to suppress the induction of the tubules were stained by these methods in severe prolifer-
ative forms of GN. We know that MIF is stored withinleukocyte adhesion molecules, intercellular adhesion
molecule-1, and vascular adhesion molecule-1. Further- the cytoplasm of cells, ready to be released upon stimula-
tion [7, 11]. Therefore, normal kidney and mild formsmore, delaying the administration of the anti-MIF anti-
body until crescentic disease was already established was of disease may represent a situation in which MIF is
not being released and so little mRNA is required toable to inhibit leukocyte accumulation, stabilize protein-
uria, partially reverse glomerular crescent formation, and maintain the cytoplasmic MIF stores. In contrast, MIF
may be rapidly released in severe forms of GN, causingfacilitate a recovery of normal renal function [24]. This
suppression of established disease was associated with a substantial increase in new MIF gene expression and
MIF protein synthesis. This rapid MIF production andan increase in serum corticosterone levels, providing evi-
dence that MIF-glucocorticoid counter-regulation oper- secretion may result in progressive renal injury seen in
these severe forms of GN.ates in GN.
Intrinsic renal cells were identified as the major source The pattern of MIF expression in normal human kid-
ney and its up-regulation in GN is similar to that de-of MIF production in human GN. In addition to glomeru-
lar and tubular epithelial cells, de novo MIF expression scribed for the two other major pro-inflammatory cyto-
kines, interleukin (IL)-1b and tumor necrosis factor-awas also seen in glomerular capillary endothelium in
severe disease cases in which there were large numbers (TNF-a) [31–35]. All three cytokines are constitutively
expressed by some tubular epithelial cells and by smallof infiltrating glomerular macrophages, suggesting that
endothelial MIF production may participate in the pro- numbers of glomerular cells, mostly podocytes. In GN,
there is an increase in the number of glomerular andcess of glomerular macrophage recruitment. Similar to
our previous finding in an experimental rat model of tubular cells expressing these three cytokines, as well
as cytokine expression by infiltrating leukocytes. Thecrescent GN [19, 20], up-regulation of MIF by glomerular
parietal epithelial cells largely contributes to glomerular promoter regions for each of these cytokine genes have a
binding site for the transcription factor nuclear factor-kBcrescent formation in human crescent GN. In addition,
MIF production by mesangial cells was seen in some (NF-kB). In vitro studies have established that NF-kB is
a key factor regulating transcription of IL-1b and TNF-acases of proliferative GN. This finding lends significance
to studies showing that rat mesangial cells produce MIF genes [36], although the function of the NF-kB binding
element in the MIF gene has yet to be determined. Thein experimental mesangioproliferative nephritis [22].
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role for macrophage migration inhibitory factor in T-cell activation.cytokines IL-1b and TNF-a have a hierarchical position
Proc Natl Acad Sci USA 93:7849–7854, 1996
in the inflammatory cascade, being able to induce pro- 10. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M,
duction of many other molecules, such as cytokines, che- Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-
induced modulator of cytokine production. Nature 376:68–71, 1995mokines, adhesion molecules, eicosanoids, nitric oxide,
11. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucalaand proteases. MIF can induce synthesis of IL-1b and R: Localization of macrophage migration inhibitory factor (MIF)
TNF-a and has a unique ability to overcome glucocorti- to secretory granules within the corticotrophic and thyrotrophic
cells of the pituitary gland. Mol Med 1:781–788, 1995coid-mediated suppression of endotoxin-induced IL-1b
12. Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macro-and TNF-a production [10]. Thus, MIF has an important phage is an important and previously unrecognized source of mac-
position at the pinnacle of the inflammatory cascade. rophage migration inhibitory factor. J Exp Med 179:1895–1902,
1994In summary, this study has demonstrated that renal
13. Bacher M, Meinhardt A, Lan HY, Dhabhar FS, Mu W, MetzMIF expression is markedly up-regulated in severe pro- CN, Chesney JA, Gemsa D, Donnelly T, Atkins RC, Bucala R:
liferative forms of human GN. Renal MIF expression MIF expression in the rat brain: Implications for neuronal function.
Mol Med 4:217–230, 1998gave a highly significant correlation with macrophage
14. Wada S, Fujimoto S, Mizue Y, Nishihira J: Macrophage migrationand T-cell infiltration, histologic damage, and renal func-
inhibitory factor in the human ovary: Presence in the follicular
tion. These results suggest that MIF may be an important fluids and production by granulosa cells. Biochem Mol Biol Int
41:805–814, 1997mediator of renal injury in progressive forms of human
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